Vaccines efficacy against infection with circulating feline calicivirus after one single injection: Comparison of Leucofeligen™ FeLV/RCP and Purevax™ RCPFeLV vaccines

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2024-09-26 DOI:10.1016/j.vaccine.2024.126393

Séverine Arcidiaco, Paul Schreiber, Laure Poincelot, Sofia Loukeri, Cynthia Lesbros, Sylvie Gueguen

{"title":"Vaccines efficacy against infection with circulating feline calicivirus after one single injection: Comparison of Leucofeligen™ FeLV/RCP and Purevax™ RCPFeLV vaccines","authors":"Séverine Arcidiaco, Paul Schreiber, Laure Poincelot, Sofia Loukeri, Cynthia Lesbros, Sylvie Gueguen","doi":"10.1016/j.vaccine.2024.126393","DOIUrl":null,"url":null,"abstract":"<div><div>Feline calicivirus (FCV) is a worldwide pathogen that affects the general health status of cats. The aim of this study was to assess the efficacy of the FCV component of two multivalent commercial vaccines after one injection. The cats assigned to the vaccinated groups received one subcutaneous injection of either the Leucofeligen™ FeLV/RCP (Virbac, France) vaccine or the Purevax™ RCPFeLV (Boehringer Ingelheim, Germany) vaccine. In the control group, the cats did not receive any vaccine. Three weeks after the vaccine injection, all the cats were inoculated with a heterologous calicivirus strain, isolated in the field. The clinical signs of calicivirosis and the viral shedding were assessed. The results demonstrated that Leucofeligen™ FeLV/RCP could protect kittens against FCV infection by reducing clinical signs and viral excretion from 3 weeks after the first injection of primary vaccination, whereas Purevax™ RCPFeLV couldn't offer the same level of protection in similar experimental conditions.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24010752","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Feline calicivirus (FCV) is a worldwide pathogen that affects the general health status of cats. The aim of this study was to assess the efficacy of the FCV component of two multivalent commercial vaccines after one injection. The cats assigned to the vaccinated groups received one subcutaneous injection of either the Leucofeligen™ FeLV/RCP (Virbac, France) vaccine or the Purevax™ RCPFeLV (Boehringer Ingelheim, Germany) vaccine. In the control group, the cats did not receive any vaccine. Three weeks after the vaccine injection, all the cats were inoculated with a heterologous calicivirus strain, isolated in the field. The clinical signs of calicivirosis and the viral shedding were assessed. The results demonstrated that Leucofeligen™ FeLV/RCP could protect kittens against FCV infection by reducing clinical signs and viral excretion from 3 weeks after the first injection of primary vaccination, whereas Purevax™ RCPFeLV couldn't offer the same level of protection in similar experimental conditions.

查看原文本刊更多论文

单次注射后疫苗对流行性猫卡里科病毒感染的预防效果：Leucofeligen™ FeLV/RCP 和 Purevax™ RCPFeLV 疫苗的比较

猫卡里科病毒（FCV）是一种影响猫总体健康状况的全球性病原体。本研究的目的是评估两种多价商业疫苗中的 FCV 成分在一次注射后的疗效。被分配到疫苗接种组的猫接受了一次 Leucofeligen™ FeLV/RCP 疫苗（法国 Virbac 公司）或 Purevax™ RCPFeLV 疫苗（德国 Boehringer Ingelheim 公司）的皮下注射。在对照组中，猫没有接种任何疫苗。注射疫苗三周后，所有猫都接种了从野外分离的异源犊牛病毒株。对钙化病的临床症状和病毒脱落情况进行了评估。结果表明，Leucofeligen™ FeLV/RCP 可在首次注射初免疫苗 3 周后通过减少临床症状和病毒排泄来保护幼猫免受 FCV 感染，而 Purevax™ RCPFeLV 在类似的实验条件下无法提供相同程度的保护。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.